

# INSPIRA TECHNOLOGIES OXY B.H.N. LTD

## FORM 6-K

(Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16)

Filed 04/15/25 for the Period Ending 04/15/25

Telephone	972-9-9664488
CIK	0001837493
Symbol	IINN
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Advanced Medical Equipment & Technology
Sector	Healthcare
Fiscal Year	12/31

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of April 2025 (Report No. 4)

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.  
(Translation of registrant's name into English)

2 Ha-Tidhar St.  
Ra'anana 4366504, Israel  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

---

---

## CONTENTS

On April 15, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first, second, and fourth paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (Registration Nos. [333-266748](#) and [333-284308](#)) and Form S-8 (Registration Nos. [333-259057](#) and [333-277980](#)), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

<u>Exhibit No.</u>	
99.1	<a href="#">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on April 15, 2025, titled “Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems.”</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 15, 2025

**Inspira Technologies Oxy B.H.N. Ltd.**

By: /s/ Dagi Ben-Noon

Name: Dagi Ben-Noon

Title: Chief Executive Officer



## **Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems**

*The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility*

RA'ANANA, Israel, April 15, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received payment from its U.S. distributor, Glo-Med Networks Inc. (“Glo-Med”), for a delivery of its INSPIRA™ ART100 systems, which are cleared by the U.S. Food & Drug Administration (“FDA”).

The revenue, in the range of the low hundreds of thousands of dollars, relates to the delivery of the INSPIRA ART100 systems, which have been recently installed at a premier U.S. academic medical center, as previously announced. In addition, additional systems are planned for installation at a second leading academic medical center. This revenue milestone represents a significant achievement in the Company’s deployment strategy, as it continues to expand its footprint in the U.S. healthcare market.

“Generating our first revenues represents a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape,” said Dagi Ben-Noon, Chief Executive Officer of Inspira. “This achievement, coupled with our successful system installation at a premier medical institution, validates both our innovative technology and our ability to work with top tier medical institutions. As we expand our clinical footprint and generate valuable real-world data, we look forward to advancing the adoption of our life-support systems among leading healthcare facilities across the United States, generating initial revenues in the process.”

The Company’s broader expansion strategy includes collaborating with additional leading medical experts and institutions to further validate its innovative approach to extracorporeal life support. The FDA-cleared INSPIRA ART100, intended for cardiopulmonary bypass procedures, circulates and oxygenates blood outside the body during cardiac surgeries. This same core technology serves as a foundational technology of the Company’s flagship INSPIRA™ ART500 system which is currently under development and is being designed to provide direct blood oxygenation for respiratory failure patients without mechanical ventilation. The INSPIRA ART500 aims to revolutionize the \$19 billion mechanical ventilation market by offering a safer alternative that allows patients to remain awake during treatment.

### **About Inspira Technologies**

Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company’s flagship INSPIRA ART500 system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company’s HYL A blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company’s pipeline products, including the INSPIRA ART500, HYL A blood sensor, and Single-use patient kit are currently in development and have not yet received regulatory approval.

For more information, visit: <https://inspira-technologies.com>

---

## **About Glo-Med Networks, Inc.**

Glo-Med, known for delivering unique healthcare solutions, collaborates with top medical device and biomedical companies worldwide to meet the growing demand for innovative medical devices and related products in domestic and international markets. Glo-Med maintains extensive access to next-generation medical products globally via long-term partnerships and relationships with medical providers and through its sister company focused on medical device servicing with a focus on hospital beds and medical mattresses, Med-Stat Consulting Services, Inc. (est. 2003). Along with larger and prominent healthcare organizations in New York and Florida as clients, Glo-Med has offices and partner companies in the U.S., Latin America, Europe, the Middle East, and Africa, providing extensive access to the global medical network.

For more information, please visit the corporate website: [www.glomednet.com](http://www.glomednet.com)

## **Forward-Looking Statement Disclaimer**

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the planned installation of additional ART100 systems at a second leading academic medical center, that the achievement of its initial revenues, coupled with its successful system installation at a premier medical institution, validates both its innovative technology and its ability to work with top tier medical institutions and its broader expansion strategy, its anticipated advancement of adoption of its life-support systems across leading healthcare facilities, the potential advantages of the INSPIRA ART100, and its aim to revolutionize the mechanical ventilation market.. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at [www.sec.gov](http://www.sec.gov).

## **Company Contact**

Inspira Technologies – Media Relations

Email: [info@inspirao2.com](mailto:info@inspirao2.com)

Phone: +972-9-9664485

## **Capital Markets & Investor Contact**

Arx | Capital Markets Advisors

North American Equities Desk

[inspirao@arxadvisory.com](mailto:inspirao@arxadvisory.com)

---